Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

June 09, 2016 07:00 ET | Source: FibroGen, Inc.

FibroGen Announces Initiation by Astellas of Phase 3 Clinical Study in Japan of Roxadustat/ASP1517 for the Treatment of Anemia of Chronic Kidney Disease Triggering $10.0 Million Milestone Payment

SAN FRANCISCO, June 09, 2016 (GLOBE NEWSWIRE) -- FibroGen, Inc. (Nasdaq:FGEN) (“FibroGen”), announced today that it will receive a $10.0 million milestone payment from Astellas Pharma Inc....
June 06, 2016 07:00 ET | Source: FibroGen, Inc.

FibroGen to Present at the Goldman Sachs 37th Annual Global Healthcare Conference

SAN FRANCISCO, June 06, 2016 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ:FGEN), announced that Chief Executive Officer, Thomas B. Neff, will be presenting at the Goldman Sachs 37th Annual Global...
May 09, 2016 16:02 ET | Source: FibroGen, Inc.

FibroGen Reports Financial Results for the First Quarter of 2016

Continued Progress in Roxadustat Phase 3 Studies; Promising Interim Pancreatic Cancer Data –Webcast Conference Call Scheduled for 4:30pm EST Today– SAN FRANCISCO, May 09, 2016 (GLOBE NEWSWIRE)...
May 02, 2016 16:05 ET | Source: FibroGen, Inc.

FibroGen to Report First Quarter 2016 Financial Results on May 9, 2016

SAN FRANCISCO, May 02, 2016 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ:FGEN), a research-based biopharmaceutical company focused on the discovery, development, and commercialization of novel...
April 20, 2016 23:00 ET | Source: FibroGen, Inc.

Promising Phase 2 Data Show Roxadustat Corrected Anemia in Chronic Kidney Disease Patients Before Intervention with Dialysis

SAN FRANCISCO, April 20, 2016 (GLOBE NEWSWIRE) -- FibroGen, Inc. (Nasdaq:FGEN) (“FibroGen”), a research-based biopharmaceutical company, today announced that the Clinical Journal of the American...
March 11, 2016 08:00 ET | Source: FibroGen, Inc.

FibroGen Announces Publication of Phase 2 Study Results Supporting the Potential of FG-3019 to Treat Patients With Idiopathic Pulmonary Fibrosis

SAN FRANCISCO, March 11, 2016 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ:FGEN) (FibroGen) announced today that the European Respiratory Journal (“ERJ”) published on-line a manuscript...
February 29, 2016 16:02 ET | Source: FibroGen, Inc.

FibroGen Announces Fiscal 2015 Financial Results

SAN FRANCISCO, Feb. 29, 2016 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ:FGEN) (“FibroGen”), a research-based biopharmaceutical company, today reported financial results for the year ended December...
February 19, 2016 07:00 ET | Source: FibroGen, Inc.

FibroGen to Report Fourth Quarter and Full Year 2015 Financial Results on February 29, 2016

SAN FRANCISCO, Feb. 19, 2016 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ:FGEN), a research-based biopharmaceutical company focused on the discovery, development, and commercialization of novel...
February 16, 2016 07:20 ET | Source: FibroGen, Inc.

FibroGen Publishes Encouraging Phase 2 Anemia Data Demonstrating Roxadustat’s Ability to Maintain Hemoglobin Levels in Patients With Chronic Kidney Disease

SAN FRANCISCO, Feb. 16, 2016 (GLOBE NEWSWIRE) -- FibroGen, Inc. (Nasdaq:FGEN) (“FibroGen”), a research-based biopharmaceutical company, today announced that the American Journal of Kidney Disease...
January 27, 2016 21:27 ET | Source: FibroGen, Inc.

FibroGen Announces Early Phase 2 Data From a Clinical Study of FG-3019 in Combination With Chemotherapy as Neoadjuvant in Locally Advanced, Unresectable Pancreatic Cancer

SAN FRANCISCO, Jan. 27, 2016 (GLOBE NEWSWIRE) -- FibroGen, Inc. (FibroGen) today announced early results from a Phase 2, randomized, open-label study of FG-3019, an investigational anti-fibrotic...